Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Arcutis Biotherapeutics's gross margin for the twelve months ending Sep 30, 2026 was 91.2%. For fiscal 2025 it was 90.2%, against 90.3% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.2% | −0.0 |
| FY2024 | Dec 31, 2024 | 90.3% | −1.4 |
| FY2023 | Dec 31, 2023 | 91.6% | +12.1 |
| FY2022 | Dec 31, 2022 | 79.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 91.3% | +0.1 |
| Q2 FY2026 | Jun 30, 2026 | 91.6% | +0.8 |
| Q1 FY2026 | Mar 31, 2026 | 90.7% | +4.1 |
| Q4 FY2025 | Dec 31, 2025 | 91.0% | +0.7 |
| Q3 FY2025 | Sep 30, 2025 | 91.2% | +3.5 |
| Q2 FY2025 | Jun 30, 2025 | 90.8% | +2.0 |
| Q1 FY2025 | Mar 31, 2025 | 86.6% | −6.8 |
| Q4 FY2024 | Dec 31, 2024 | 90.3% | +6.9 |
| Q3 FY2024 | Sep 30, 2024 | 87.7% | −9.2 |
| Q2 FY2024 | Jun 30, 2024 | 88.8% | +3.7 |
| Q1 FY2024 | Mar 31, 2024 | 93.4% | +21.6 |
| Q4 FY2023 | Dec 31, 2023 | 83.4% | – |
| Q3 FY2023 | Sep 30, 2023 | 96.9% | – |
| Q2 FY2023 | Jun 30, 2023 | 85.0% | – |
| Q1 FY2023 | Mar 31, 2023 | 71.8% | – |
See a number that looks wrong?